Abstract:The establishment of primary tumor cells in distant organs, termed metastasis, is the principal cause of cancer mortality and is a crucial therapeutic target in oncology. Thus, it is critical to establish a better understanding of metastatic progression for the future development of improved therapeutic approaches. Indeed, such development requires insight into the timing of tumor cell dissemination and seeding of distant organs resulting in occult lesions. Following dissemination of tumor cells from the primary tumor, they can reside in niches in distant organs for years or decades, following which they can emerge as an overt metastasis. This timeline of metastatic dormancy is regulated by interactions between the tumor, its microenvironment, angiogenesis, and tumor antigen-specific T-cell responses. An improved understanding of the mechanisms and interactions responsible for immune evasion and tumor cell release from dormancy would help identify and aid in the development of novel targeted therapeutics. One such mediator of dormancy is myeloid derived suppressor cells (MDSC), whose number in the peripheral blood (PB) or infiltrating tumors has been associated with cancer stage, grade, patient survival, and metastasis in a broad range of tumor pathologies. Thus, extensive studies have revealed a role for MDSCs in tumor escape from adoptive and innate immune responses, facilitating tumor progression and metastasis; however, few studies have considered their role in dormancy. We have posited that MDSCs may regulate disseminated tumor cells resulting in resurgence of senescent tumor cells. In this review, we discuss clinical studies that address mechanisms of tumor recurrence including from dormancy, the role of MDSCs in their escape from dormancy during recurrence, the development of occult metastases, and the potential for MDSC inhibition as an approach to prolong the survival of patients with advanced malignancies. We stress that assessing the impact of therapies on MDSCs versus other cellular targets is challenging within the multimodality interventions required clinically.

Implication of the Extracellular Matrix in Metastatic Tumor Cell Dormancy

Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Cell Dormancy and Tumor Refractory

A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy

Mechanisms of disseminated cancer cell dormancy: an awakening field

Developing a dormancy-associated ECM signature in TNBC that is linked to immunosuppressive tumor microenvironment and selective sensitivity to MAPK inhibitors

Mesenchymal Stem Cell-Secreted Exosomes and Soluble Signals Regulate Breast Cancer Metastatic Dormancy: Current Progress and Future Outlook

Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis.

The Relationship Between Mesenchymal Stem Cells and Tumor Dormancy

Role of myeloid-derived suppressor cells in tumor recurrence

The Bone Microenvironmental Effect in the Dormancy of Cancer

The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets

The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?

The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis

Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis

Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

Targeting Extracellular Matrix Interaction in Gastrointestinal Cancer: Immune Modulation, Metabolic Reprogramming, and Therapeutic Strategies

Recent progress on the effect of extracellular matrix on occurrence and progression of breast cancer

Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy

Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces